Pharsight

Drugs that contain Latanoprostene Bunod

1. List of Vyzulta drug patents

VYZULTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058467 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 9 months from now)

US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 9 months from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 9 months from now)

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of VYZULTA before it's patent expiration?
More Information on Dosage

VYZULTA family patents

5

United States

5

European Union

2

Norway

2

Costa Rica

2

Argentina

2

Spain

2

Korea, Republic of

1

Israel

1

South Africa

OA

1

OA

1

Denmark

1

Mexico

1

Australia

1

Hong Kong

1

Slovenia

1

Hungary

1

Morocco

1

Uruguay

1

Brazil

1

Croatia

1

Guatemala

1

Cyprus

1

Malaysia

1

Peru

1

Poland

1

RS

1

China

1

Ecuador

1

Taiwan, Province of China

1

Georgia

1

Ukraine

1

Japan

EA

1

EA

1

Canada

1

Tunisia

1

Panama

1

New Zealand

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic